Collection of Biological Samples From Patients With Rare Neurological Diseases
ConditionNervous System Diseases
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age6-99
SponsorUniversity Hospital, Toulouse
About this trial
The aim of this project is to improve biological collections of patients presenting rare neurological disorders with known or suspected autoimmune origin. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
all patients with neurological disorders, with known or probable autoimmune involvement. This includes adults and children and peripheral and/or central nervous system symptoms.
Social coverage up to date.
Disqualifiers
Patients with neurological damage from which the autoimmune character can be excluded.
Known anemia and hemoglobin <10 g / dl
Patients under protective supervision (guardianship, curators)
Pregnant or breastfeeding woman
Trial population
patients followed at the Toulouse University Hospital and presenting rare neurological disorders with known or suspected autoimmune origin
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Blood collection on admission and longitudinally
Biological/VaccineBiological samples will be collected in the normal diagnosis and follow-up process. Only blood will be taken in larger quantity (8 tubes of 7mL).
Treatment groups
1,000 Participants
are divided into 1 treatment groupGroup A: patients with rare autoimmune neurological diseases1 intervention
Trial outcomes
Primary outcomes
1
Building a collection of biological samples and clinical-biological data from patients with rare autoimmune neurological diseases
Blood sampling
Time frame
Day 0 and through study completion, an average of 1 yearSecondary outcomes
1
Identification of new autoantibodies.
ELISA
Time frame
Day 0 and through study completion, an average of 1 year2
Identification of biomarkers regarding the severity (such as cytokines, axonal damages...) in order to help the therapeutic decisions.
Analysis of the phenotypic profiling of blood immune cells by multicolor fluorescence-activated cell sorter (FACS) analysis and of the transcriptomic profiling of blood immune cells by RNA sequencing
Time frame
Day 0 and through study completion, an average of 1 year3
Exploration of the pathophysiological mechanisms of rare autoimmune neurological pathologies.
Knock-out or knock-in animal models for one specific protein will be used to determine in vivo if the pathophysiological mechanisms of rare autoimmune neurological disorder can be induced by the abnormal expression of this protein.
Time frame
Day 0 and through study completion, an average of 1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov